Neuropsychiatric Disorders

Improving Addiction Treatment by Targeting Cognitive Deficits

by

People struggling with substance use disorders often have difficulties with memory, attention, planning, and decision-making. New research explores how these cognitive deficits relate to treatment outcomes and whether targeting them could improve addiction recovery. Key Facts: Cognitive deficits are common in people with substance use disorders, especially relating to memory, attention, self-control, and reward-based decision-making. …

Read more

Ketamine’s Long-Lasting Antidepressant Effects via “Trapping” in NMDA Receptors & LHb

by

Researchers uncover a surprising molecular mechanism that explains ketamine’s exceptionally long-lasting antidepressant effects. Key Facts: Ketamine’s antidepressant effects last for days after its concentration drops to low, ineffective levels only an hour after administration. This contrasts starkly with ketamine’s short 13-minute half-life in the body. Ketamine continues blocking NMDA receptors and suppressing activity in the …

Read more

Exercise as an Antidepressant: The Best Natural Treatment for Depression?

by

Depression is one of the most common mental health issues, affecting over 320 million people globally. Research shows that exercise may be an effective treatment option for many battling this disabling condition. Key Facts: Exercise has comparable antidepressant effects to medications and psychotherapy in clinical trials. Both aerobic and resistance training reduce depressive symptoms, with …

Read more

Best Antidepressants for Preventing Relapse in Major Depression (Latest Research)

by

Researchers conducted a comprehensive analysis comparing 20 antidepressants to identify the most effective options for preventing relapse in patients with major depressive disorder (MDD). Their findings suggest desvenlafaxine, paroxetine, venlafaxine and vortioxetine balance efficacy and tolerability best for maintenance treatment. Key Facts: The analysis included 34 high-quality clinical trials with over 9,300 patients total. All …

Read more

Revolutionizing Depression Treatment: Novel Rapid-Acting Antidepressants & Emerging Drug Targets

by

Major depressive disorder (MDD) is a global health crisis affecting over 300 million people. While available antidepressants help some patients, treatment is far from satisfactory for many. Exciting research into rapid-acting agents like ketamine and psilocybin combined with exploration of novel drug targets finally offers real hope for transformational change in how depression is treated. …

Read more

Running Therapy vs. Antidepressants: Efficacy for Depression, Anxiety, Health

by

New research finds that regular running is just as effective as antidepressants for treating depression and anxiety, and leads to better physical health outcomes. Key Facts: In a study of 141 patients, running therapy and antidepressant medication had comparable effects on rates of remission (no longer meeting diagnostic criteria) from depression/anxiety disorders. However, running led …

Read more

mGluR2/3 Inhibitors as Antidepressants: Targeting Glutamate Receptors in Depression

by

Depression affects over 300 million people globally. Current antidepressants have limited efficacy and slow onset of action. New research shows promise for compounds targeting metabotropic glutamate receptors 2 and 3 (mGluR2/3) as fast-acting antidepressants with fewer side effects. Key Facts: 1/3 of depressed patients are treatment-resistant with current antidepressants mGluR2/3 inhibitors show robust, rapid (within …

Read more

Major Depression Linked to High VCAM-1 Levels & Gray Matter Loss

by

New research reveals that increased inflammation, indicated by higher levels of a protein called VCAM-1, is associated with decreased gray matter and altered brain connectivity in patients with major depressive disorder (MDD). These brain changes also correlate with VCAM-1 levels. Key Facts: MDD patients had higher blood VCAM-1 levels than healthy controls Higher VCAM-1 related …

Read more

Metabolic Biomarkers & Future Depressive Symptoms: Is There a Link?

by

A new study examined whether metabolic biomarkers assessed through a high-throughput method are associated with future depressive symptoms. The results suggest the metabolites may not play a direct role in depression development. Key Facts: Researchers investigated associations between 121 metabolic measures and depressive symptoms at 7-year follow-up. Some metabolites showed tendencies for links with more …

Read more

Continuous Theta Burst Stimulation (cTBS) Ineffective for Depression? (New Meta-Analysis Reports No Benefit)

by

A new meta-analysis found that continuous theta burst stimulation (cTBS), a novel form of brain stimulation therapy, does not appear to be more effective than sham (placebo) stimulation for treating symptoms of major depression. Key Facts: cTBS is a type of repetitive transcranial magnetic brain stimulation that aims to modulate activity in certain brain regions …

Read more

+ Load more